SCHEMBL4778654

SCHEMBL4778654

COC(=O)CN1C(=O)CCC(N2C(=O)c3cscc3C2=O)C1=O

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 2/20 0.38
CRBN Q96SW2 2/20 0.38
PPARG P37231 2/20 0.36
POLB P06746 1/20 0.36
LMNA P02545 1/20 0.36
ALDH1A1 P00352 2/20 0.35
AKR1B1 P15121 2/20 0.33
TP53 P04637 1/20 0.33
MDM2 Q00987 1/20 0.33
PIN1 Q13526 1/20 0.32
PIN4 Q9Y237 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
CYP3A4 P08684 1/20 0.32
MAPK1 P28482 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4778940 0.88 PIN1 (0.47) PPARGLMNAALDH1A1PIN1PIN4
SCHEMBL4776701 0.83 DDB1 (0.38) DDB1CRBNPPARGPOLBLMNA
SCHEMBL633493 0.83 HDAC6 (0.37) CRBNPPARGPOLBLMNAHDAC6
SCHEMBL4780293 0.82 CRBN (0.35) DDB1CRBNALDH1A1MAPK1
SCHEMBL10054602 0.82 DDB1 (0.37) DDB1CRBNPPARGPOLBLMNA
SCHEMBL4779854 0.81 ALDH1A1 (0.32) DDB1CRBNALDH1A1
SCHEMBL4777647 0.80 DDB1 (0.36) DDB1CRBNPPARGLMNAKMT2A
SCHEMBL12004014 0.80 MAP1LC3B (0.35) DDB1CRBNALDH1A1KMT2A
SCHEMBL4779857 0.80 CYP19A1 (0.35) DDB1CRBNALDH1A1
SCHEMBL4777947 0.78 HTT (0.37) DDB1CRBNLMNAALDH1A1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524742-B2 Use of 5H-thioeno(3,4-c)pyrrole-4,6-dione derivatives as tumor necrosis factor inhibitor TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2013-09-03 US claimed
US-20120220631-A1 USE OF 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AS TUMOR NECROSIS FACTOR INHIBITOR TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2012-08-30 US claimed
US-8183260-B2 small molecule, low toxicity, high efficiency, high economic value; 5-(2,6-dioxopiperidin-3-yl)-5H-thieno(3,4-c)pyrrole-4,6-dione: TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2012-05-22 US claimed
US-8524742-B2 Use of 5H-thioeno(3,4-c)pyrrole-4,6-dione derivatives as tumor necrosis factor inhibitor TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2013-09-03 US disclosed
US-8524742-B2 Use of 5H-thioeno(3,4-c)pyrrole-4,6-dione derivatives as tumor necrosis factor inhibitor TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2013-09-03 US disclosed
US-8524742-B2 Use of 5H-thioeno(3,4-c)pyrrole-4,6-dione derivatives as tumor necrosis factor inhibitor TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2013-09-03 US disclosed
EP-1964842-B1 5H-THIENO [3,4-c]PYRROLE-4, 6-DIONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR TIAN JIN HEMAY BIO TECH CO LTD (CN) 2012-09-12 EP disclosed
EP-1964842-B1 5H-THIENO [3,4-c]PYRROLE-4, 6-DIONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR TIAN JIN HEMAY BIO TECH CO LTD (CN) 2012-09-12 EP disclosed
US-20120220631-A1 USE OF 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AS TUMOR NECROSIS FACTOR INHIBITOR TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2012-08-30 US disclosed
US-20120220631-A1 USE OF 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AS TUMOR NECROSIS FACTOR INHIBITOR TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2012-08-30 US disclosed
US-20120220631-A1 USE OF 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AS TUMOR NECROSIS FACTOR INHIBITOR TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2012-08-30 US disclosed
US-8183260-B2 small molecule, low toxicity, high efficiency, high economic value; 5-(2,6-dioxopiperidin-3-yl)-5H-thieno(3,4-c)pyrrole-4,6-dione: TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2012-05-22 US disclosed
US-8183260-B2 small molecule, low toxicity, high efficiency, high economic value; 5-(2,6-dioxopiperidin-3-yl)-5H-thieno(3,4-c)pyrrole-4,6-dione: TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2012-05-22 US disclosed
US-8183260-B2 small molecule, low toxicity, high efficiency, high economic value; 5-(2,6-dioxopiperidin-3-yl)-5H-thieno(3,4-c)pyrrole-4,6-dione: TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2012-05-22 US disclosed
EP-1964842-A1 5H-THIENO [3,4-c]PYRROLE-4, 6-DIONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR Tian Jin Hemay Bio-Tech Co., Ltd. (CN) 2008-09-03 EP disclosed
EP-1964842-A1 5H-THIENO [3,4-c]PYRROLE-4, 6-DIONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR Tian Jin Hemay Bio-Tech Co., Ltd. (CN) 2008-09-03 EP disclosed
US-20080176900-A1 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2008-07-24 US disclosed
US-20080176900-A1 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2008-07-24 US disclosed
US-20080176900-A1 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220631-A1 USE OF 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AS TUMOR NECROSIS FACTOR INHIBITOR TNF, TPMT, TNFRSF1A DDB1 790/4885CRBN 1305/4885PPARG 2603/4885
US-20080176900-A1 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TNF, TNFRSF1A, CD40 DDB1 1951/4885CRBN 938/4885PPARG 3679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.